



AMENDMENTS TO THE CLAIMS

Claims 1-12 (Canceled)

Claim 13. (currently amended). ~~The compound of Claim 1 or a pharmaceutically acceptable salt or ester prodrug derivative of the compound~~ represented by the formula:



or

or a mixture thereof.

Claim 14. (canceled)

Claim 15. (currently amended). The salt derivative of a compound of claim ~~1~~13 wherein the salt is sodium or potassium.

Claim 16. (currently amended). A pharmaceutical formulation comprising a compound of ~~claim 1~~claim 13, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent.

Claim 17. (currently amended). A formulation according to claim 16 for treating osteoporosis comprising:

Ingredient (A1): a vitamin D receptor modulator of claim ~~13~~13, or a pharmaceutically acceptable salt thereof;

Ingredient (B1):

one or more co-agents selected from the group consisting of:

- a. estrogens,
- b. androgens,
- c. calcium supplements,
- d. vitamin D metabolites,
- e. thiazide diuretics,
- f. calcitonin,
- g. bisphosphonates,
- h. SERMS, and
- i. fluorides; ~~and~~

~~Ingredient (C1): optionally, a carrier or diluent.~~

Claim 18. (previously presented). The formulation of claim 16 wherein the weight ratio of (A1) to (B1) is from 10:1 to 1:1000.

Claim 19. (currently amended) A formulation according to claim 16 for treating psoriasis comprising:

Ingredient (A2): a vitamin D receptor modulator of claim ~~13~~13;

Ingredient (B2):

one or more co-agents that are conventional for treatment

~~osteoporosis~~psoriasis selected from the group consisting of:


- a. topical glucocorticoids ,
- b. salicylic acid,
- c. crude coal tar; ~~and~~

~~Ingredient (C2): optionally, a carrier or diluent.~~

Claim 20. (currently amended). The formulation of claim ~~18~~19 wherein the weight ratio of (A2) to (B2) is from 1:10 to 1:100000.


Claim 21-30. (canceled)

31. (new) A compound according to claim 13 represented by the formula:




or a pharmaceutically acceptable salt thereof.

32. (new) A compound represented by the formula:




or a pharmaceutically acceptable salt thereof.

33. (new) A compound represented by the formula:



or



or a mixture thereof,

wherein R is methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, morpholinoethyl, and N,N, diethylglycolamide.

34. (new) A pharmaceutical formulation according to claim 16 provided for oral administration.

35. (new) A method of treating osteoporosis by administration to a mammal a compound according to claim 13 or a pharmaceutically acceptable salt thereof.

36. (new) A method according to claim 35 comprising administering a dose between 0.0001 mg/kg/day to 5 mg/kg/day of body weight.

37. (New) A method of treating a mammal to alleviate the pathological effects of at least one of: osteoporosis, leukemia, and psoriasis.